Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition

A major obstacle to curing chronic myeloid leukaemia (CML) is residual disease maintained by tyrosine kinase inhibitor (TKI)-persistent leukemic stem cells (LSCs). These are BCR-ABL1 kinase-independent (1, 2), refractory to apoptosis (3, 4) and serve as a reservoir to drive relapse or TKI-resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Scott, Mary T., Korfi, Koorosh, Saffrey, Peter, Hopcroft, Lisa E.M., Kinstrie, Ross, Pellicano, Francesca, Guenther, Carla, Gallipoli, Paolo, Cruz, Michelle, Dunn, Karen, Jorgensen, Heather G., Cassels, Jennifer E., Hamilton, Ashley, Crossan, Andrew, Sinclair, Amy, Holyoake, Tessa L., Vetrie, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538532/
https://ncbi.nlm.nih.gov/pubmed/27630125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0263
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados